Benitec Biopharma Inc.

For the period ended Jun 30, 2026. Filed Sep 14, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2026 · Filed Sep 14, 2026

BNTC$9.28-6.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Stockholders’ Equity

(in thousands, except share amounts)

Common Stock · AdditionalPaid-in · Accumulated · AccumulatedOtherComprehensive · TotalStockholders’
	Shares	Amount	Capital	Deficit	Loss	Equity
Balance at June 30, 2024	10,086,119	$1	$238,398	$(190,259)	$(892)	$47,248
Issuance of common stock and pre-funded warrants sold for cash, net of offering costs of $2,252	2,043,000	1	28,207	—	—	28,208
Exercise of pre-funded warrants	2,374,583	—	—	—	—	—
Exercise of Series 2 warrants	1,553,927	—	2,999	—	—	2,999
Exercise of common warrants, net of offering cost of $67	10,192,840	—	39,278	—	—	39,278
Share-based compensation	—	—	17,426	—	—	17,426
Foreign currency translation gain	—	—	—	—	53	53
Net loss	—	—	—	(37,917)	—	(37,917)
Balance at June 30, 2025	26,250,469	$2	$326,308	$(228,176)	$(839)	$97,295
Issuance of common stock sold for cash, net of offering costs of $6,266	7,740,370	1	98,229	—	—	98,230
Exercise of common warrants	161,927	—	625	—	—	625
Exercise of pre-funded warrants	200,276	—	—	—	—	—
Exercise of Series 2 warrants	63,792	—	123	—	—	123
Share-based compensation	—	—	26,410	—	—	26,410
Foreign currency translation loss	—	—	—	—	(124)	(124)
Net loss	—	—	—	(45,546)	—	(45,546)
Balance at June 30, 2026	34,416,834	$3	$451,695	$(273,722)	$(963)	$177,013

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.